INS and infection: Importantly, the infection rate with Eversense was shown to be three to five times lower than that reported with insulin infusion pumps.15 Therefore, given the stable performance across cycles reported here, low rate of risks reported previously, and preference for Eversense shown in the majority of patients in previous studies, the benefits of Eversense outweigh the risks and provide patients with a long-term implantable CGM system that many prefer over short-term transcutaneous systems.